araag2/HINT huggingface dataset:
Clinical trial NCT00641537 (phase 3, status: completed)
Conditions: relapsing-remitting multiple sclerosis
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: cladribine, placebo, cladribine, cladribine, placebo
SMILES: [Mg++].[Cl-].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Mg++].[Cl-].[Cl-], [Mg++].[Cl-].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Randomized in Trial 25643 and satisfied one of the following:

               -  Completed randomized treatment course and scheduled visits for the full 96 weeks;
                  or

               -  Did not complete the randomized treatment course in Trial 25643 but elected to
                  receive rescue treatment with Rebif®, another beta-interferon, or glatiramer
                  acetate and completed scheduled clinic visits for the full 96 weeks; or

               -  Did not complete the randomized treatment course in Trial 25643, declined rescue
                  with Rebif®, another beta-interferon, or glatiramer acetate and still completed
                  scheduled clinic visits for the full 96 weeks; or

               -  Did not complete the randomized treatment course in Trial 25643, were not
                  eligible for rescue option with Rebif®, and still completed scheduled clinic
                  visits for the full 96 weeks

          -  Male or female, between 18 and 65 years of age (inclusive, at time of informed consent
             for Trial 25643)

          -  No medical history or evidence of latent tuberculosis infection (LTBI) or tuberculosis
             (TB), as evidenced by TB skin test or chest X-ray

          -  All of the following laboratory hematologic parameters evaluated as normal (as define
             below, inclusively) within 28 days of first dosing of blinded study medication at
             study Day 1:

               -  Hemoglobin = 11.6 to 16.2 gram per deciliter (g/dL)

               -  Leukocytes (total white blood cell) = 4.1 to 12.3*10^3 per microliter

               -  Absolute lymphocyte count (ALC) = 1.02 to 3.36*10^3 per microliter

               -  Absolute neutrophil count (ANC) = 2.03 to 8.36*10^3 per microliter

               -  Platelet count = 140 to 450*10^3 per microliter

          -  Other protocol-defined inclusion/exclusion criteria may apply

        Exclusion Criteria:

          -  Participants who were not enrolled in Trial 25643

          -  Participant has moderate to severe renal impairment

          -  Use of mitoxantrone, total lymphoid irradiation, myelosuppressive therapy, campath-1h,
             cyclophosphamide, azathioprine, methotrexate or natalizumab at any time during and
             since Trial 25643

          -  Use of cytokine or anti-cytokine therapy, intravenous immunoglobulin (IVIG) or
             plasmapheresis at any time during and since Trial 25643

          -  Treatment with oral or systemic corticosteroids or adrenocorticotropic hormone within
             28 days before Study Day 1
Clinical trial NCT00159861 (phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: sildenafil citrate
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with pulmonary arterial hypertension caused by primary PAH, associated with
             connective tissue disease or following surgical repair of a congenital heart lesion

        Exclusion Criteria:

          -  PH other than PAH
Clinical trial NCT00548691 (phase 3, status: completed)
Conditions: anemia
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: ferric carboxymaltose, standard medical care (smc)
SMILES: [Fe]
Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female 18 to 85 years of age

          -  NDD-CKD Patients

          -  TSAT </= 25%

          -  Hgb </= 11.5

          -  Ferritin </= 300

          -  HD-CKD Patients

          -  TSAT </= 30%

          -  Hgb </= 12

          -  Ferritin </= 500

        Exclusion Criteria:

          -  Previous participation in a FCM trial

          -  Known Hypersensitivity to FCM

          -  History of anemia other that anemia due to chronic renal failure

          -  Current history of GI bleeding

          -  Received IV Iron within the last 30 Days

          -  Anticipated need for surgery

          -  Malignancy history

          -  AST or ALT greater than normal

          -  Received an investigational drug within 30 days of screening

          -  Pregnant or sexually active females who are not willing to use an effective form of
             birth control
Clinical trial NCT00413413 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan/amlodipine 80/5 mg, valsartan 80 mg, valsartan 160 mg
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients >= 18 years and < 86 years

          -  Patients with essential diastolic hypertension

          -  At visit 1, the patient must have mean sitting diastolic blood pressure >= 95 mmHg and
             < 10 mmHg; patients treated with antihypertensive medication must have a mean sitting
             diastolic blood pressure < 100 mmHg

          -  At visit 2, patients must have a mean sitting diastolic blood pressure of >= 95 mmHg
             and < 100 mmHg

          -  At visit 3, patients must have a mean sitting diastolic blood pressure of >= 90 mmHg
             and < 110 mmHg

        Exclusion Criteria:

          -  Severe hypertension >= 180/110 mmHg

          -  Known or suspected contraindications, including a history of allergy or
             hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical
             structures

          -  Inability to discontinue all prior antihypertensive medications safely for a maximum
             period of up to 28 days prior to Visit 2

          -  History of hypertensive encephalopathy, cerebrovascular accident or transient ischemic
             attack, myocardial infarction or other types of revascularization

          -  Malignant hypertension

          -  All patients with Type I diabetes and those patients with Type 2 diabetes who are not
             well controlled based on the investigator's clinical judgment

          -  Pregnant or nursing women

          -  History of heart failure

          -  Angina pectoris

          -  Second or third degree heart block

          -  Life threatening or symptomatic arrhythmias

          -  Clinically significant valvular heart disease

          -  Evidence of a secondary form of hypertension

          -  Known or moderate malignant retinopathy

          -  Evidence of hepatic disease

          -  Evidence of renal impairment

        Other protocol-defined exclusion criteria may apply.
Clinical trial NCT00073021 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: asacol 800 mg (mesalamine), asacol 400 mg (mesalamine)
SMILES: NC1=CC(C(O)=O)=C(O)C=C1, NC1=CC(C(O)=O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  male or female between 18 and 75 years of age;

          -  have a confirmed diagnosis of ulcerative colitis with the extent varying from
             proctitis to pancolitis;

          -  currently demonstrating moderately active disease

        Exclusion Criteria:

        Patients will be excluded from admission to the study if they have/are:

          -  a history of allergy or hypersensitivity to salicylates or aminosalicylates;

          -  a history of extensive small bowel resection (>1/2 the length of the small intestine)
             causing short bowel syndrome;

          -  current renal or hepatic disease;

          -  participated in any drug or device clinical study within 30 days of entry;

          -  currently enrolled in any other clinical study;

          -  received any oral, intravenous, intramuscular, or rectally administered
             corticosteroids within 1 month prior to the Baseline Visit;

          -  received any other topical rectal therapy during the week prior to the Screening
             Visit;

          -  received immunomodulatory therapy including, but not limited to, 6-mercaptopurine,
             azathioprine, cyclosporine, or methotrexate within 3 months prior to the Baseline
             Visit;

          -  received a dose of mesalamine-containing compound by any route from which more than
             1.6 g/day of mesalamine was available within 1 week prior to the Screening Visit
             (NOTE: 4 g/day of sulfasalazine and 4.5 g/day of balsalazide are equivalent to 1.6
             g/day of mesalamine);

          -  received antibiotics, other than topical antibiotics, within 1 week prior to the
             Screening Visit;

          -  received aspirin (except for cardioprotective reasons up to a maximum dose of 325
             mg/day) or NSAIDs within 1 week prior to the Baseline Visit;

          -  if female, positive pregnancy test, or lactating.
Clinical trial NCT01519700 (phase 3, status: completed)
Conditions: chemotherapy associated neutropenia, breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ep2006, filgrastim
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with histologically proven breast cancer, eligible for neoadjuvant or
             adjuvant myelosuppressive chemotherapy

          2. Women ≥ 18 years of age

          3. Estimated life expectancy of more than six months

        Exclusion Criteria:

          1. Previous or concurrent malignancy except non-invasive non-melanoma skin cancer, in
             situ carcinoma of the cervix, or other solid tumor treated curatively, and without
             evidence of recurrence for at least ten years prior to study entry

          2. Any serious illness or medical condition that may interfere with safety, compliance,
             response to the products under investigation and their evaluation, e.g.:

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00194077 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: aripiprazole, placebo
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients ages 4-9 years (inclusive)

          -  Patients who are anticipated to have a Young Mania Rating Scale (Young et al. 1978) of
             15 or higher at baseline

          -  Meet DSM-IV criteria for bipolar disorder type 1 or 2, cyclothymia, or bipolar
             disorder not otherwise specified (BP NOS) based on the results of both a
             semi-structured diagnostic research assessment (K-SADS-PL supplemented with mood
             disorder sections from the WASH-U K-SADS) (Geller et al., 2001; Kaufman et al., 1997)
             and a clinical interview with a child and adolescent psychiatrist.

        Exclusion Criteria:

          -  Patients who have a history of intolerance to APZ at doses of 0.1mg/kg/day

          -  Patients who have experienced a manic episode with a documented APZ dose as
             monotherapy treatment of 0.2 mg/kg/day

          -  Patients with an active neurological/medical disorder for which treatment with APZ
             would be contraindicated

          -  Patients with clinical evidence of autistic disorder, Asperger's disorder, Rett's
             syndrome or other pervasive developmental disorders

          -  Patients with clinical evidence of mental retardation

          -  Patients who are known to be allergic or hypersensitive to aripiprazole

          -  Patients who are unable to swallow pills/capsules

          -  Patients for whom the need for hospitalization during the course of the study appears
             likely

          -  Patients who have a general medical or neurological condition (including clinically
             significant abnormalities on screening laboratories) that may be considered to be the
             etiology of the patient's mood disorder

          -  Patients who have a general medical or neurological condition for which treatment with
             an atypical antipsychotic would be contraindicated (e.g. tardive dyskinesia)

          -  Patients who have a general medical or neurological condition that could interfere
             with the interpretation of clinical response to APZ treatment

          -  Patients taking psychotropic agents (other than psychostimulants) within one week of
             baseline (2 weeks for fluoxetine; 3 days for psychostimulants)
Clinical trial NCT00111189 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: placebo, paliperidone palmitate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who meet the diagnostic criteria for schizophrenia according to DSM-IV-TM for
             at least 1 year before screening

          -  have a PANSS score of <120

          -  have a body mass index (BMI) >/=15.0 kilogram (kg)/meter (m)2

          -  and have resided at the same address for at least 30 days

        Exclusion Criteria:

          -  Patients unable to provide their own consent

          -  have been involuntarily committed to psychiatric hospitalization

          -  have primary, active DSM-IV-TM diagnosis other than schizophrenia

          -  who have a DSM-IV-TM diagnosis of active substance dependence within 3 months before
             screening (nicotine and caffeine are not exclusionary)

          -  have a history of treatment resistance as defined by failure to respond to 2 adequate
             trials (minimum of 4 weeks at a therapeutic dose) of different antipsychotic
             medications

          -  have a history of any severe preexisting gastrointestinal narrowing or inability to
             swallow the medication whole with water

          -  have a history of neuroleptic malignant syndrome (NMS)

          -  are at significant risk of suicidal or violent behavior

          -  current presence of any significant or unstable medication condition

          -  treatment with any protocol disallowed therapies

          -  clinically significant result from screening laboratory or ECG.
Clinical trial NCT00417911 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Symptomatic myeloma diagnosis according to criteria in attachment 3

          -  ASCT is performed or has been performed in the last five weeks (time limit two weeks
             for patients randomised at 2nd transplantation) as a part of primary therapy

          -  Signed informed consent given prior to any study related activities have been
             performed

        Exclusion Criteria:

          -  Prior exposure to bortezomib

          -  Allogeneic transplantation scheduled as a part of the primary treatment

          -  Neuropathy > Grade 2 (neurological symptoms interfering with ADL)

          -  Non-secreting myeloma

          -  Other concurrent disease making bortezomib treatment unsuitable

          -  Positive pregnancy test (only applicable for women with childbearing potential)

          -  Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin,
             if an indwelling catheter is used

          -  Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure
             (Attachment 6, NYHA Classification of Cardiac Disease), uncontrolled angina,
             clinically significant pericardial disease, or cardiac amyloidosis

          -  History of hypotension or has decreased blood pressure (sitting systolic blood
             pressure [SBP] £100 mmHg and/or sitting diastolic blood pressure [DBP] £60 mmHg)

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study

          -  Have received an experimental drug or used an experimental medical device within 4
             weeks prior to inclusion into the study
Clinical trial NCT01432236 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women of any race or ethnicity who are at least 18 years of age.

          -  Adult women and men with a diagnosis of fibromyalgia and stable depression (major
             depressive disorder, depression not otherwise specified (NOS), or dysthymia) who have
             been taking an antidepressant (SSRI or SNRI) primarily for their depression for at
             least 3 months.

        Exclusion Criteria:

          -  Have failed pregabalin treatment due to lack of improvement of symptoms at doses of
             greater than or equal to 300 mg daily, cannot tolerate pregabalin or any pregabalin
             ingredient, or participated in a pregabalin clinical trial. If the subject has taken
             pregabalin and discontinued for reason other than lack of improvement or intolerance,
             then they will be eligible. Pregabalin use within the last 30 days (prior to V1) is
             not permitted.

          -  Patients with severe or unstable depression are not eligible.

          -  Patients with other types of pain or conditions that may make it difficult to evaluate
             fibromyalgia symptoms are not eligible

          -  Any subject considered at risk of suicide or self harm based on investigator judgment
             and/or the details of a risk assessment
Clinical trial NCT00254774 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: quetiapine fumarate or valproate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent, men and women aged ³18 to £65 years with diagnosis of DSM-IV
             criteria for bipolar I or II disorder, most recent episode manic, hypomanic, mixed or
             depressive with Rapid Cycling.

        Exclusion Criteria:

          -  Substance or alcohol dependence, female patients who are pregnant, lactating or at
             risk of pregnancy, diagnosis of schizophrenia or borderline personality disorder or
             antisocial personality disorder, history of seizure disorder, acute suicidal or
             external aggressive behaviour, legal incapacity or indication for treatment against
             the will of the patient by law.
Clinical trial NCT00531817 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tocilizumab, placebo, permitted dmards
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, ≥18 years of age

          -  Active rheumatoid arthritis of >6 months duration

          -  Received permitted DMARDs each at a stable dose for at least 7 weeks prior to baseline

        Exclusion Criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid
             arthritis

          -  Major surgery within 8 weeks prior to screening or planned within 6 months following
             randomization

          -  Unsuccessful treatment with a biologic agent, including an anti-TNF agent

          -  Previous treatment with tocilizumab
Clinical trial NCT00060489 (phase 3, status: completed)
Conditions: bipolar disorder, depression, bipolar
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: seroquel (quetiapine fumarate) tablets
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Written Informed Consent;

          -  Bipolar disorder with most recent episode depressed;

          -  Outpatient status

        Exclusion Criteria:

          -  Patients with a current Axis I disorder other than bipolar disorder within 6 months of
             screening;

          -  Patients whose current episode of depression exceeds 12 months or is less than 4 weeks
Clinical trial NCT00002764 (phase 3, status: completed)
Conditions: endometrial cancer, kidney cancer, metastatic cancer, ovarian cancer, pheochromocytoma, sarcoma
ICD codes: N85.00, N85.01, N85.02, N99.85, D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: doxorubicin hydrochloride, ifosfamide
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven soft tissue sarcoma with pulmonary
        metastases for which radical metastasectomy is feasible Eligible subtypes: Malignant
        fibrous histiocytoma Liposarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma
        Leiomyosarcoma Neurogenic sarcoma Unclassified sarcoma Angiosarcoma (including
        hemangiopericytoma) Miscellaneous sarcoma (including mixed mesodermal tumors of the uterus)
        Ineligible subtypes: Alveolar rhabdomyosarcoma Kaposi's sarcoma Rhabdomyosarcoma of any
        type Malignant mesothelioma Chondrosarcoma Neuroblastoma Dermatofibrosarcoma Osteosarcoma
        Epithelioid sarcoma Primitive neuroectodermal tumor Ewing's sarcoma No extrapulmonary
        disease Previously treated local recurrence allowed Patients with primarily metastatic
        disease must have undergone radical treatment of primary tumor according to local protocols
        Reevaluation of metastases required before randomization

        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: WHO 0-1 Life expectancy: Not
        specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 120,000/mm3
        Hepatic: Bilirubin no greater than 1.25 times normal Renal: Creatinine no greater than 1.6
        mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No history of
        cardiovascular disease Other: No other severe medical illness (including psychosis) No
        prior or concurrent other primary malignancy except adequately treated carcinoma in situ of
        the cervix or basal cell carcinoma

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy for metastatic disease Prior neoadjuvant or adjuvant chemotherapy for primary
        soft tissue sarcoma allowed if cumulative dose of doxorubicin no greater than 200 mg/m2 At
        least 1 year since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: Not
        specified Surgery: See Disease Characteristics